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The PTPN22 locus is one of the strongest risk factors outside of themajor histocompatability complex
that associates with autoimmune diseases. PTPN22 encodes lymphoid protein tyrosine phosphatase
(Lyp) which is expressed exclusively in immune cells. A single base change in the coding region of this
gene resulting in an arginine to tryptophan amino acid substitution within a polyproline binding
motif associates with type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Hashimo-
tos thyroiditis, Graves disease, Addison’s disease, Myasthenia Gravis, vitiligo, systemic sclerosis juve-
nile idiopathic arthritis and psoriatic arthritis. Here, we review the current understanding of the
PTPN22 locus from a genetic, geographical, biochemical and functional perspective.
Crown Copyright  2011 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. Open access under CC BY-NC-ND license.1. Introduction
Lymphoid protein tyrosine phosphatase (Lyp) is encoded by the
PTPN22 locus on chromosome 1p13.3–13.1. A single nucleotide
polymorphism in PTPN22 has been reported as an autoimmune
susceptibility locus that associates with type 1 diabetes [1–8],
rheumatoid arthritis [8–15], systemic lupus erythematosis
[10,16–18], Hashimotos thyroiditis [19], Graves disease [20], Add-
isons disease [21,22], Myasthenia Gravis [23], vitiligo [24–26], sys-
temic sclerosis [27], and juvenile idiopathic arthritis [14,28]
suggesting that allelic variants of PTPN22 could predispose to a
more general autoimmune diathesis. Genetic studies indicate that
the association is highly reproducible in populations that carry the
mutant allele. In spite of these validation studies, and the contin-
ued growth in genetic association studies with disease in man,
the functional consequences of a single base change at the DNA le-
vel of PTPN22 remain unresolved. Here, we examine the current
understanding of Lyp function and explore the evidence providing
insights into why the PTPN22 locus is a biologically plausible can-
didate autoimmune susceptibility gene.sevier B.V. on behalf of Federation2. Protein tyrosine phophatases and protein tyrosine kinases
are immune cell gatekeepers
Protein Tyrosine Phosphatases (PTPs) and Protein Tyrosine Ki-
nases (PTKs) are enzymes that speciﬁcally catalyse the reversible
addition or release of phosphate groups from tyrosine residues
on signalling intermediates. Broadly speaking, PTKs amplify signals
whilst the mode, tempo and duration of the signal are governed by
PTPs. PTPs and PTKs are divided into two groups: receptor (mem-
brane bound-RPTP or RPTK) or non-receptor (cytoplasmic-NRPTP
or NRPTK). These signalling intermediates are chemical messen-
gers that are recruited when transducing messages from the extra-
cellular environment into the cell and lead ultimately to changes in
cell behaviour. Phosphorylation/dephosphorylation by PTKs and
PTPs on inhibitory or activatory tyrosine on signalling intermedi-
ates are the equivalent of molecular on/off switches. Post-transla-
tional modiﬁcations of proteins by the addition or release of
phosphate groups on tyrosine alters enzymatic activity or binding
afﬁnity of functional domains which act to propagate or inhibit a
series of molecular interactions and reactions. Protein phosphory-
lation status can therefore be viewed as a fundamental, coordi-
nated process allowing cells to adapt to gradual or sudden
changes in the environment and must be tightly controlled. This
is particularly true in the context of an immune response, where
cells must be activated under appropriate circumstances to ﬁght
infections and tumours, but avoid self directed responses that cul-
minate in autoimmunity [29].of European Biochemical society. Open access under CC BY-NC-ND license.
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man phosphoproteome and at least 57 of these are expressed in
lymphocytes. PTPs and PTKs control the highly complex and dy-
namic nature of signal transduction pathways associated with
many cellular processes as diverse as differentiation, migration,
apoptosis, proliferation and activation of immune cells [30]. The
tonic inhibition of basal PTK activation requires PTPase activity
to be several orders of magnitude higher than that of PTK activity.
PTPs were once thought largely to play housekeeping functions by
non-speciﬁcally binding and dephosphorylating signalling inter-
mediates. It has, however, become increasingly evident that PTPs
bind with exquisite speciﬁcity to certain signalling intermediates
through protein–protein interaction domains or lipid binding mod-
ules, and in many cases play non-redundant roles. This notion is
exempliﬁed in the context of the immune system by immunopa-
thology exhibited by mouse models in which certain phosphatases
are defective in function or expression, and implicates signalling
intermediates as important messengers that are responsible for
setting thresholds of immune activation. These mutations can be
naturally occurring or engineered and point to the importance of
phosphatase function in maintaining immune homeostasis.
For example, a loss-of-function of PTP SHP-1 mutation, which
negatively regulates TCR signalling leads to the motheaten pheno-
type characterised by immunodeﬁciency, lymphoproliferation
and autoimmunity [31,32]. A gain in function of CD45, which has
been shown to be a positive regulator of TCR and BCR signalling,
predisposes mice to an autoimmune-like syndrome [33]. While
mouse models provide insight into the importance of phosphatase
function, little is known about phosphatases that contribute to dis-
ease in humans. In recent years, genome wide association studies
have repeatedly identiﬁed candidate PTPs that associate with auto-
immune disease. These include PTPN2, PTPRC, UBASH3A, PTPN11,
PTPRT and PTPN22, pointing to dysregulation of protein tyrosine
phosphorylation as a crucial facet of immunopathology. This re-
view focuses on PTPN22, since genetic variants of this phosphatase
remain one of the strongest genetic risk factors for autoimmune
disease outside of the major histocompatibility complex (MHC).
It follows that a better understanding of the biology of PTPN22/
Lyp may unravel new and possibly common mechanisms that pro-
mote autoimmune disease.Table 1
PTPN22 associates with autoimmune diseases. The number of studies pooled is
indicated in brackets. Based on references [1–34].
Autoimmune disease Odds ratio
Rheumatoid arthritis (15) 1.3–2.13
TID (7) 1.5–2.39
SLE (5) 1.42–2.56
Hashimotos thyroiditis 1.62–1.77
Addisons 1.69
Juvenile idiopathic arthritis 1.17–1.7
Wegeners granulomatosis 1.76
Graves disease 1.7
Systemic sclerosis 1.09
Vitiligo 1.82
Psoriatic arthritis 1.493. Genetic associations between allelic variants and
autoimmunity
In recent years, human genetic studies have identiﬁed a grow-
ing number of gene candidates that associate with autoimmune
disease. There are three approaches that can be utilised when
investigating genetic variants that might contribute to the devel-
opment of autoimmune disease states. These include candidate
gene association studies, linkage analysis in multiplex families
and genome wide association studies (GWAS). Statistical tools
have been developed to complement each approach, but a lack of
appreciation for careful case controls when conducting candidate
gene studies and low statistical power of genetic linkage analysis
has compromised the validity of some of these studies [34]. A
strong publication bias of candidate gene studies that report posi-
tive ﬁndings has also been documented [35]. Results from these
studies should therefore be treated with caution until they have
been validated unambiguously in replication studies.
GWAS are currently considered the most effective way of min-
ing for new disease associated gene variants since this approach is
purely discovery driven, conducted by scanning whole genomes
without any particular hypothesis in mind. GWAS can be limited
by the fact that only common gene variants are identiﬁed because
of the reference genomes used and small sample sizes. In manycases the actual causative genetic variants cannot be precisely
identiﬁed because of linkage disequilibrium between causal vari-
ants and the haplotype tagging single nucleotide polymorphisms
(SNPs) employed to detect variants across the genome. Haplotype
deﬁning SNPs in people who have been diagnosed with autoim-
mune disorders provide clues that, after ﬁne genetic mapping at
selected loci, must then be investigated in a biological framework
to understand its contribution to disease development. This in turn
can pave the way for exploring potential therapeutic interventions
by understanding pathological alterations. Common disease vari-
ants may point to pathways that might become plausible targets
for therapeutic intervention. However, it should be noted that a re-
cent study that sequenced two T1D associated genes in 13 715
individuals revealed that European populations, probably as a re-
sult of recent accelerating population growth, harbour many rare,
deleterious variants that may contribute signiﬁcantly to disease
burden in these populations, but which are not detected through
conventional GWAS [36]. Hypothesis driven investigations of po-
tential gene candidates in the diseased state are the only way rare
variants can currently be discovered.
4. PTPN22 associates with autoimmunity
In 2004 a seminal paper by Bottini et al. reported an association
between a SNP in PTPN22 and T1D in two distinct populations,
using a candidate gene approach [4]. A transitional mutation
changing a cytosine to a thymine at position 1858 in the coding re-
gion of the PTPN22 gene resulted in a single amino acid change of
an arginine to a tryptophan at codon 620 in exon 14. This R620W
amino acid substitution is located in a polyproline motif, PLPXR,
within the Lyp phosphatase protein thought to be involved in bind-
ing to SH3 domains during protein–protein interactions [37].
Within 1 year SLE and RA were reported to also associate with
R620W and following a multitude of studies it has now become
evident that this polymorphism is an allelic variant associated with
susceptibility to a growing number of autoimmune diseases (Ta-
ble 1). Strikingly, the association is highly reproducible, found in
many different populations and is restricted to disorders that usu-
ally have a strong autoantibody component. A perplexing gradient
frequency of the allele has been reported to exist.
5. The geographical distribution of R620W in European
populations
The highest frequency of the allele is found in the most north-
erly and easterly reaches of the continent in Finland (15%) and
the Ukraine (14.1%) and their neighbouring lands. Moving south-
west, the frequency of the allele gradually decreases to around
7% in France and Spain and is found in only 2–3% of Italian and Sar-
dinian populations (Fig. 1 [1–5,9,10,12,14,20,21,28,38,39]) [40].
Fig. 1. The frequency distribution of the minor T allele across the European continent. An East to West gradient is demonstrated. Adapted from www.eduplace.com/ss/maps/.
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lele at a frequency of 6–9%. In Asian and African populations the al-
lele is virtually absent [11]. This observation indicates that the
polymorphism in PTPN22 probably arose late in human evolution
in a European population(s). It may confer a selective advantage.
In support of this notion, extended haplotype homozygosity stud-
ies have indicated that the PTPN22 locus may be under positive
selection, at least in populations of European ancestry [41].
There has been interest as to whether R620W may protect car-
riers from infectious disease because there have been reports of
potential autoimmune susceptibility loci protecting individuals
from environmental pathogens [42,43]. Studies have indicated that
carriers of R620W may be protected from tuberculosis [44,45].
R620W is a risk factor in the development of invasive pneumococ-
cal disease, indicating that PTPN22 is a susceptibility gene for auto-
immunity and certain infections [46]. Other studies investigating
the involvement of R620W in the protection from or susceptibility
to Hepatitis C infection [47], Trypanosoma Cruzi infection [48] and
brucellosis [49] have demonstrated no differences between control
groups and R620W carriers. Further association studies of R620W
with infection might provide useful information about the fre-
quency distribution of the allele and its possible relationship with
an infectious agent.
6. The discovery of Lyp and PEP
Catalytic domains of PTPs are highly conserved and can thus
be targeted using degenerate primers in PCR reactions that will
amplify non-conserved ﬂanking regions. The resultant PCR prod-
uct can then be compared to known PTP sequences and vali-
dated or investigated further if a novel stretch of DNA is
identiﬁed. Using this method, Lyp was identiﬁed in 1999 as a
105kDa Class 1 NRPTP, belonging to the proline-, glutamic
acid-, serine- and threonine-rich (PEST) family of phosphatases.
Its mouse orthologue, proline enriched phosphatase (PEP), was
discovered in 1992 [50,51].Structurally Lyp and PEP consist of an N-terminal catalytic do-
main, an interdomain and a C-terminal binding domain that con-
tains four polyproline-rich motifs (P1–P4) that act as potential
binding sites for Src Homology 3 (SH3) protein domains. Lyp and
PEP are the most divergent example of phosphatase orthologues
between human and murine species (89% and 61% homology in
their catalytic and non-catalytic domains respectively) although
most of these differences lie within the interdomain that may be
important for regulating phosphatase activity [52,53]. There have
been some hints in the literature of subtle biochemical differences
between PEP and Lyp and so extrapolation from murine models to
human biology should be undertaken with some caution.
7. Lyp isoforms
In humans, Lyp exists in three splice forms designated Lyp1–3
[50,54] (Fig. 2). The full length protein of 807aa, Lyp1, is the most
abundant of the 3 isoforms and has been the subject of all func-
tional studies to date. Lyp2 is the shortest splice variant and con-
tains only the ﬁrst P1 motif within the N-terminal whilst Lyp3
has a 28 amino acid deletion between P1 and P2. The functions
of Lyp2 and Lyp3 are not known. Lyp can be membrane bound
through interactions with other proteins, or cytosolic, but the sub-
cellular location of the different isoforms has not yet been re-
ported. The expression of Lyp is conﬁned exclusively to
haematopoietic cells and a clear hierarchy exists in the expression
proﬁle across immune cell lineages with respect to Lyp abundance
[30]. Natural Killer cells and neutrophils express the highest levels
of Lyp, followed by CD8+ T cells while CD4+ T cells and monocytes
express the lowest levels of Lyp [11]. Lyp expression in activated
versus non-activated cells requires further investigation.
8. The function of Lyp in immune cells
Immune cells must cooperate to mount and maintain an appro-
priate response and dysregulation of any cell type could lead to
Fig. 2. Lyp isoforms 1–3. A schematic demonstrating the exons (vertical bars) and introns (horizontal lines) of Lyp1–3. Approximate sizes of exons and introns are shown. Lyp
1 is 807aa. Lyp2 is a truncated form of Lyp1 with a bigger exon 16 totalling 691aa. Lyp3 is 779aa and has a 28bp deletion in exon 15. Red denotes the changes in exon
composition. Adapted from Zang et al 2010.
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much effort has been invested in understanding the various path-
ways that trigger immune cell activation, and the relative contribu-
tion of the different lineages to an immune response. T and B cell
receptors represent some of the best studied signalling machinery
and even though they recognise peptides through completely dif-
ferent antigen receptor structures, they share many PTKs, PTPs
and adaptor molecules [55–57]. The Src and Syk kinase families
are crucial positive regulators of immune cell activation through
B and T cell receptors as well as other immunoreceptors like Fc
receptors (FcR) and Natural Killer Cell receptors termed killer
immunoglobulin receptors. At least some of the Src and Syk kinase
family are targeted and inactivated by Lyp as demonstrated by
substrate trapping experiments. Lyp may therefore represent a
key regulator of immunoreceptor dependent activation of many
leukocyte functions. Despite its expression in all immune cells,
only T cell substrates of Lyp have been reported.
8.1. Substrate trapping in T cells
Although our understanding of Lyp function in T cells has
broadened since the association of R620W with autoimmune dis-
ease there is still a lack of data describing signalling pathways
other than that of the TCR. Further study of Lyp is required in the
lymphoid compartment but is also merited in the context of other
immune cells to generate ideas about fundamental biological pro-
cesses that could lead to new hypotheses with respect to autoim-
mune diseases.
In order to delineate signalling pathways, it is important to
identify target substrates of signalling intermediates. To this end,
Flint et al. have developed a method whereby important PTP cata-
lytic residues in the N-terminus are mutated and the resultant
non-functional catalytic domain is then fused to a glutathione-S-
transferase protein allowing substrates to interact with but not
disassociate from a PTP due to the lack of catalytic activity that
leads to post-translational protein modiﬁcations and the release
of modiﬁed substrate [58]. This method, or a variation thereof,
has been widely employed as the substrate trap is sufﬁciently sta-
ble to allow subsequent isolation of PTP-substrate complexes by
co-immunoprecipitation. Substrate trapping should always be
interpreted with care, especially when using candidate substrates
puriﬁed fromwhole cell lysates or PTP catalytic domain-GST fusion
proteins as they do not respect binding domain interactions or sub-
cellular localisation of their native counterparts, both of whichmay
be intimately linked. This is because protein interaction domainshave been shown to be essential for subcellular location as well
as protein binding [59,60]. In additional, immune cells can display
many different levels of activation that may also contribute to sub-
strate localisation and recognition [30].
Substrate trapping experiments in the human Jurkat T cell line
indicate that Lyp interacts with Lck, f-associated protein 70
(ZAP70), Vav, CD3e, TCRf, valosine containing protein (VCP),
Grb2and c-Cbl (Fig. 3) [61–63]. In addition to the substrates of
Lyp, PEP targets FynT [62]. These signalling intermediates are
known to participate in proximal signalling events following T cell
receptor (TCR) engagement with MHC-peptide complexes. One
exception to this is VCP, which has many apparently unrelated
functions including retrotranslocation of unfolded proteins into
the endoplasmic reticulum, the homotypic fusion of smooth endo-
plasmic reticulum membranes, NF-jB activation, reformation of
golgi cisternae and nuclear envelope reassembly [64]. The signiﬁ-
cance of this ﬁnding is currently unknown.
8.2. T cell receptor signalling
T cells are educated in the thymus and emerge with a functional
and distinct TCR that recognises peptide in complex with MHC. The
selection processes that occur in the thymus aim to generate TCR’s
that have a high afﬁnity for foreign peptide in complex with MHC
but T cells with a high afﬁnity for self peptide are deleted. In the
periphery, T cells, each of which bear a speciﬁc TCR, can undergo
clonal expansion following an encounter with a foreign peptide
in complex with MHC displayed by a professional antigen present-
ing cell. This paradigm is the cornerstone of adaptive immunity,
where T cells can perform a variety of effector functions following
their activation and proliferation.
Following the engagement of the TCR and co-receptors, signal-
ling intermediates proximal to the cell membrane are sequentially
activated. Lck is a critical positive regulator of TCR signalling and is
either activated near or recruited to immunoreceptor tyrosine acti-
vation motifs (ITAMS) CD3 and TCR-f that are then phosphory-
lated. The doubly phosphorylated ITAM motifs in turn recruit
ZAP-70 via its two tandem SH2 domains. The interaction between
the SH2 domain and the phosphorylated ITAM motif releases ZAP-
70 from its auto inhibited state, exposing activatory tyrosine resi-
dues that can be phosphorylated by Lck or in trans by ZAP-70 itself
leading to increased catalytic activity. ZAP-70 then phosphorylates
a number of downstream adaptors, scaffolds and signalling mole-
cules including linker of activated T cells (LAT) and SH2 domain
containing lymphocyte protein (SLP-76). The activation of T cells
Fig. 3. Lyp acts on multiple proximal T cell receptor signalling intermediates. Lyp is thought to be targeted to the proximal TCR signalling machinery by an interaction of the
ﬁrst polyproline domain in Lyp and an SH3 domain on Csk. Csk, in turn binds phosphorylated PAG/CBP via an SH3 domain. Substrate trapping experiments indicate that Lyp
can interact with Lck, ZAP-70, TCR f and CD3e ITAMS, Grb2 and Vav. Lck is thought to regulate Lyp activity but the nature and context of this interaction is not yet clear.
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eventually to fully functional, differentiated T cells.
8.3. The role of Lyp in T cell receptor signalling
Lyp targets various signalling intermediates involved in TCR sig-
nalling and may act at several points in the signalling cascade. Src
and Syk family kinases are key activators of T cell receptor signal-
ling and are negatively regulated by Lyp (Fig. 3) [61,65]. The Src
family kinase Lck is phosphorylated on an inhibitory tyrosyl resi-
due Y505 under steady state by C-terminal Src kinase (Csk) creat-
ing an internal SH2 binding domain which facilitates the so called
‘‘tail bite’’ inactive conformation of Lck [66,67]. Csk is located in the
cytoplasm but can target the plasma membrane through direct
interactions with a high afﬁnity SH2 binding site on a transmem-
brane protein found in lipid rafts termed Csk binding protein
(CBP) or protein associated with GEMS (PAG). It has been proposed
that Lyp may be targeted to the plasma membrane through inter-
actions with Csk which results in a Csk/Lyp complex anchored to
the cell membrane by PAG (Fig. 4). The positioning of Lyp and
Csk near the cell membrane allows for access to their target sub-
strates which are localised in the same region. An unusually high
afﬁnity interaction between the P1 domain motif PLPXR on Lyp
and an SH3 binding domain on Csk promotes the formation of
the Csk/Lyp complex that may act to synergistically inhibit proxi-
mal TCR signalling [62,68]. Following TCR engagement, PAG is
dephosphorylated by an unknown phosphatase releasing the Csk/
Lyp complex which may then form homodimers through SH3 do-
mains of Csk releasing Lyp and inhibiting its own catalytic activity
[69].Using a human derived T cell line (Jurkat cells), the Gjorloff–
Wingren group showed that mouse PEP localises at the cell mem-
brane but recent studies using mouse cells failed to identify the
phosphatase in lipid rafts [65,70]. The context in which the Lyp/
Csk complex is targeted to the plasma membrane requires further
investigation.Following the activation of RPTP CD45, a positive regulator of
TCR signalling, Lck is activated through dephosphorylation of the
inhibitory Y505 residue. Lck then auto phosphorylates activatory
tyrosyl residue Y394 within the activation loop of the kinase do-
main. Lyp is thought to dephosphorylate Lck at this activatory site
[61]. Recent studies indicate that activated Lck may also regulate
Lyp function by phosphorylating an inhibitory tyrosine residue,
Y536, thereby inactivating Lyp [71]. The precise stoichiometry of
the interactions that promote Lyp phosphorylation by Lck is com-
plex and remains to be determined, but Csk micro clusters may
facilitate this interaction through SH2 binding sites that allows
the docking of Lck and subsequent phosphorylation and inactiva-
tion of Csk associated Lyp. Clariﬁcation of the sequence of events
that govern inhibition of Lck by Csk and Lyp is also required, since
Csk preferentially targets activated Lck that is phosphorylated at
Y394, as demonstrated by in vitro kinase assays and phosphopep-
tide mapping [72]. The regulation of Lck has also been brought into
question in recent years since it is becoming evident that acute
dephosphorylation of Y505 may not be necessary for Lck activation
and TCR signalling. Instead, at steady state, Lck exists in differen-
tially activated pools with substrate targeting occurring as a result
of spatial temporal regulation [73,74]. Clariﬁcation of why there
are primed pools of Lck at steady state and the implications of
these ﬁndings with respect to TCR signalling is important to further
our understanding of the role Lyp plays during these events.
Once activated, Lck phosphorylates immunoreceptor tyrosine-
based activation motifs (ITAMS) on TCRf, CD3e, CD3c and CD3d
creating high afﬁnity binding sites for the tandem SH2 domains of-
ZAP-70, a Syk family protein tyrosine kinase that contains multiple
inhibitory and activatory tyrosyl residues located at Y292, Y492
and Y319, Y493 respectively [75,76]. ZAP-70 is phosphorylated
by Lck on residues Y319, Y493 and is activated following its
recruitment through tandemly arranged SH2 domains to phos-
phorylated ITAM motifs located on TCR subunits. ZAP-70 then
targets multiple substrates and is itself a substrate of Lyp through
Fig. 4. Lyp and Csk inactivate Lck. The Lyp/Csk interaction is mediated through the ﬁrst polyproline motif on Lyp and the SH3 domain of Csk. PAG, when phosphorylated by
Fyn, acts as a scaffold and recruits Csk through an SH2 domain that binds phosphorylated proteins. Csk phosphorylates Y505 creating an SH2 binding site that results in an
internal fold and partial deactivation of Lck. For Lck to be fully inactivated, Lyp must dephosphorylate the activatory Y394 residue within the kinase domain for Lck to
inactivate its catalytic activity.
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target ZAP-70 through the E3 ubiquitin ligase c-Cbl which docks
onto the phosphorylated inhibitory residue of ZAP-70 promoting
inactivation through dephosphorylation of activatory residues by
Lyp. In support of this notion, Lyp has been reported to target c-
Cbl, but this relationship remains unclear [77].
ZAP-70 phosphorylates proximal TCR signalling intermediates
and adaptors that are targeted and perhaps negatively regulated
by Lyp including Grb2 and Vav. Grb2 positively regulates TCR acti-
vation in cooperation with CD28 by activating Ras. It has been pos-
tulated that Grb2 might play a dual role by delivering Lyp to CTLA-
4 (a relative of CD28 and a negative regulator of co-stimulation)
which has SH3 and SH2 domains capable of binding adaptor mol-
ecules thereby participating in downregulation of TCR signalling
mediated by CTLA-4 [30,78]. Studies have shown that Lyp and
CTLA-4 upregulate and co-localise following TCR activation [50].
Vav, an atypical guanine exchange factor involved in cytoskele-
tal rearrangements and immune synapse formation is targeted and
activated by ZAP-70 and inactivated by Lyp [79]. Studies have yet
to address the contribution of Lyp in regulating Vav function. Given
the importance of the immune synapse in governing the outcome
of APC-lymphocyte and lymphocyte-target cell interactions, stud-
ies exploring the role of Lyp in regulating such processes are war-
ranted. Interestingly, a family member of Lyp, PTP-PEST, has been
shown to dephosphorylate cytoskeletal and focal adhesion pro-
teins CAS, PYK2, FAK and paxillin that mediate integrin activation
[80,81]. PTP-HCSF is also implicated in regulating cytoskeletal
dynamics [82]. Taken together, the PTP-PEST family function as
important regulators of the cytoskeleton and adhesion molecules
in immune cells.
These observations imply that Lyp plays an important function
in the tonic inhibition of TCR function as well the shutting down of
T cell activation after engagement of the TCR complex. Since Lyp is
upregulated following TCR engagement, it is quite feasible that
modulation of signalling in effector T cells is an important functionof this phosphatase. Characterisation of the PEP deﬁcient mouse
revealed an increase in the proportion of effector and memory pop-
ulations of T cells which would be entirely in keeping with the
putative functions of Lyp. To date, there have been no reports that
PEP deﬁcient mice are more susceptible to autoimmune or lym-
phoproliferative disease. One group have shown, however, that
mice deﬁcient of PEP which also harbour a CD45 SNP encoding a
constitutively active phosphatase that positively regulates antigen
receptor signalling cooperate to break tolerance [83].
8.4. The role of Lyp in B cell signalling
Because B cells share much of their signalling machinery with T
cells it is likely that Lyp may regulate proximal B cell receptor sig-
nalling in a similar fashion, but substrate trapping experiments
have not been undertaken in B cells. There is some evidence that
there may be impairment of signalling in human individuals carry-
ing the R620W variant (as discussed below). The PEP deﬁcient
mouse, on the other hand, shows no alteration in signalling
through the BCR as evidenced by normal calcium mobilisation fol-
lowing BCR engagement. The impact of PEP null mutants on other
haematopoietic lineages has not yet been reported [101].
9. Functional studies of mutant Lyp in T cells
The R620Wmutation functions in an autosomal dominant fash-
ion with increased clinical penetrance in carriers who are homozy-
gous. Understanding precisely how and why this allelic variant
contributes to disease development is of considerable interest from
both a biological and therapeutic point of view.
The arginine-tryptophan substitution within the P1 domain of
Lyp at position 620 and the resulting autoimmune risk is difﬁcult
to study because our knowledge about the biochemistry of native
Lyp and its functional importance remain limited. The expression
proﬁle of Lyp across all immune cells and immune cell precursors
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to prioritise when investigating functional differences between
R620 and W620. In addition to R620W, other PTPN22 variants have
been reported to associate with or confer resistance to the develop-
ment of autoimmune disease. For example, an R263Q mutant has
been shown to be protective against SLE and RA and is reportedly
a loss-of-function variant as demonstrated by in vitro phosphatase
assays [84]. There are also reports of a SNP found within the pro-
moter region ofPTPN22 that associates with RA and T1D in an Asian
cohort, leading to increased Lyp mRNA transcripts [85,86].Whether
the increase in mRNA correlates with higher expression levels of
Lyp is not known.
The mutation in the P1 domain of Lyp has been proposed to dis-
rupt the binding of R620W to Csk [4] as compared to R620. Despite
these two molecules having opposing kinase/phosphatase activity,
they both serve to inhibit T cell function, possibly synergistically
[62]. Disruption of the Csk/Lyp complex might then lead to altered
thresholds of antigen receptor signalling affecting the education of
T cells in the thymus or B cells in the bonemarrow, and/or activation
of naive T and B cells and effector/memory cell populations.
9.1. Studies of R620W in immortalised cell lines
Two groups have addressed the functional consequences of
R620W in Jurkat cell transfectants [83,87]. Vang et al. used a lucif-
erase NFAT/AP1 reporter to determine the effects of R620 versus
W620 following T cell stimulation with anti-CD3 and anti-CD28.
By transfecting cells with different concentrations of R620 or
W620, it was shown that the mutant phosphatase inhibits NFAT/
AP1 much more efﬁciently in comparison to its non-disease asso-
ciated counterpart. A phosphatase assay using a peptide modelled
on Lck, a physiological substrate of Lyp, that directly monitored the
enzyme kinetics of R620 and W620 demonstrated that the W620
variant was catalytically more active, leading to a gain of phospha-
tase activity and an associated attenuation of TCR signalling.
Zikherman et al., on the other hand, used as a readout phos-
phorylation of the MAPK Erk after transfecting Jurkat cells with
R620 or W620 either alone or in conjunction with Csk and then
stimulated T cells through the TCR/CD3 complex. Phospho-Erk
was signiﬁcantly increased in cells co-expressing W620 and Csk.
In addition, it was shown that calcium mobilisation in cells co-
expressing W620 and Csk was more efﬁcient in comparison to
R620 and Csk. These results suggest that the mutant phosphatase,
when co-expressed with Csk, is a loss-of-function variant leading
to increased TCR signalling following stimulation.
The differences in these two studies could be in part due to the
different readouts used to measure TCR responses or to the use of
different stimuli to initiate signalling. The signiﬁcance of co-
expressing Csk and Lyp, which reveals a previously masked hypo-
morphic effect of the disease associated variant, could be crucial
and should be investigated further. Most studies using unmanipu-
lated primary human cells indicate that R620W is gain-of-function.
9.2. Studies of R620W in primary human cells
In addition to using human T cell lines, Vang et al. studied T cell
activation thresholds in the context of R620W using primary T cells
and demonstrated reduced IL-2 production, decreased activity of
transcription factors NFAT/AP1 and reduced calcium mobilisation
in response to anti-CD3 and anti-CD28 stimulation as compared
to cells harbouring wild type R620 [87].These results should be
interpreted with caution because the authors used primary cells
from patients with T1D and it is possible that other autoimmune
susceptibility genes encoding functionally and/or immunologically
related proteins may be acting independently or in cooperation
with R620W leading to the aforementioned cellular effects.Reduced TCR signalling has also been reported by two other
groups in healthy individuals (to exclude the effects of disease or
drug treatment) as well as patients with T1D, autoimmune thy-
roiditis and RA [88,89].Both of these studies demonstrate blunted
calcium ﬂux following TCR stimulation in healthy individuals and
patients that were heterozygous for R620W with an even bigger
negative effect on calcium mobilisation seen in homozygous indi-
viduals. Interestingly, T cell proliferation, a less sensitive and more
distal reading of TCR signalling was shown to be profoundly de-
creased in one study [88], but not in another [89]. Rieck also re-
ported decreased levels of IL-4 and IL-10 expression and
expansion of the memory T cell pool in R620W healthy donors,
as determined by the frequency of CD4+, CD45RO+ cells.
In another study using primary T cells derived from Myasthenia
Gravis sufferers, an increase in the number of cells producing IL-2
(using ELISpot) was shown in R620W carriers compared to non-
carriers, but the measurement of secreted IL-2 was not undertaken,
making these data difﬁcult to interpret [90]. One way to reconcile
these studies, when taken together, would be that increased num-
bers of T cells in R620W carriers might respond to stimulation,
accounting for the increase% of IL-2+ T cells, but the magnitude
of IL-2 response by individual cells is decreased.
Together these studies ﬂag up two important questions. First,
how does a mutation outside the catalytic domain lead to in-
creased enzyme activity? Second, how could an apparent attenua-
tion of TCR signalling lead to autoimmune disease? The complex
regulation of PTPs through oxidation events that favour intramo-
lecular formation of inhibitory disulphide bridges, inhibitory/acti-
vatory tyrosine, serine and threonine phosphorylation sites,
internal binding sites and pseudophophatases makes it difﬁcult
to delineate the mechanism by which R620W might function as
a gain-of-function mutant [91–93]. Recent studies have shown that
Lck dependent phosphorylation of Lyp on an inhibitory tyrosine
residue might be an important regulatory mechanism which posi-
tively inﬂuences TCR signalling [71].The interaction between Lyp
and Csk is proposed to facilitate the interactions between Lck
and Lyp. R620W cannot bind Csk efﬁciently and so this mutant
may be a gain-of-function by virtue of its failure to be appropri-
ately negatively regulated by Lck in vivo. Nonetheless, this model
would not explain why, in vitro, R620W has increased phosphatase
activity [4].Others have reported a negative regulatory S35 site lo-
cated near the catalytic domain that is phosphorylated by PKC [94].
Direct interaction between the interdomain and the catalytic do-
main of Lyp and PEP has also been postulated as an important reg-
ulatory mechanism leading to decreased phosphatase activity but
the trigger and context of this interaction remains unknown
[52,53].
The second question pertaining to how hyporesponsive T cells
might lead to autoimmunity may be more straightforward. Studies
in SKG mice have demonstrated that attenuation of TCR signalling
due to a loss-of-function ZAP-70 mutation leads to impaired ZAP-
70 and dysregulated thymic selection. Our laboratory has also
demonstrated the importance of reduced IL-2 production in this
model, in the context of skewed Th cell differentiation (Somenzi
and Cope, unpublished data). Thus, immunodeﬁciency manifested
by defective TCR signalling can, rather counter-intuitively, lead to
autoimmunity. The allelic series of ZAP-70 mutants described by
Goodnow and co-workers highlights how this defective state can
have subtle effects on distinct thymic and peripheral T cell subsets
within both effector and regulatory compartments [95].
9.3. Functional studies using B cells
In considering B cells, signalling is apparently unperturbed in
PEP null mice (there are however altered B cell pools and hyper-
gammaglobulinaemia)but signalling in human B cells harbouring
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tion with R620W might point to intrinsic B cell anomalies or al-
tered help/activation by T cells or both. Studies using B cells
derived from R620W carriers demonstrate smaller memory pools
that are hyporesponsive to stimulation through the BCR in terms
of proliferation, display reduced basal level phosphorylation of sig-
nalling intermediates and tyrosine phosphorylation following
stimulation, indicating a more active phosphatase. What is intrigu-
ing about B cell studies is that naive cells seem unaffected by
R620W. These results imply that Lyp may have an important role
in modulating B cell signalling after activation and its role there-
fore in tonic inhibition, at least in B cells, may be a minor one. This
may have as much to do with differential expression of Lyp during
activation and differentiation than with Lyp phosphatase function.
In fact, studies using the PEP/ mouse indicate that signalling in
naïve T cells is also normal. Taken together these results suggest
that in terms of signalling, Lyp appears to play a more important
role in the memory and effector cell pools when compared to naïve
lymphocytes. The observation that expression of both Lyp and PEP
are upregulated in activated T cells may be relevant [30].
10. How does R620W contribute to disease development?
Studies indicate that there are biological differences between
the common Lyp R620 and the disease associated Lyp R620W var-
iant. How these differences might manifest in autoimmune disease
remains to be uncovered. There is still no clear consensus as to
whether R620W is a gain- or loss-of-function variant and there is
a possibility that in the future there may be newly discovered func-
tions of the mutant phosphatase. It is not inconceivable that
R620Wmay exert both gain- and loss-of-function activity in differ-
ent pathways but within the same cell. Another possibility is that
the mutant Lyp may have different (or opposing) effects in cells
of different lineages, or that the mutant has opposing activities in
different pathways in the same cell.
The most obvious subset of immune cells that are inextricably
linked to autoimmunity are lymphocytes but the coordination of
an immune response requires the participation of all immune cells
and the origin of an adaptive autoimmune response may not nec-
essarily be due to intrinsic defects in the lymphoid compartment.
For example, dendritic cells express high levels of Lyp and are
responsible for presenting antigen to and polarising Th cells. Inap-
propriate activation of T cells may therefore arise as a consequence
of aberrant antigen presenting cell function leading to the develop-
ment of autoimmune disease.
One possibility by which R620W might contribute to disease is
through changes in thresholds of thymic selection. The involve-
ment of Lyp during positive and negative selection has not been re-
ported but its high expression in thymocytes might point to an
important function during T cell education. Interestingly, the thy-
mus is one of the only tissue in which all three Lyp isoforms can
be detected [54]. If the disease associated variant turns out to be
gain-of-function, high afﬁnity self-reactive TCR expressing T cells
might escape negative selection resulting in an expanded reper-
toire of autoreactive T cells and an augmented predisposition to
autoimmune disease. Conversely, a loss-of-function R620W mu-
tant may act on the very few cells that, per chance, escape negative
selection, leading to enhanced and/or sustained T cell activation
and driving T cell differentiation of effector T cells in the periphery,
leading ultimately to an autoimmune phenotype.
An alternative explanation for autoimmune disease develop-
ment in individuals carrying R620W is its effect on T regulatory
cells (Tregs). Experiments in the early 1990s by Sagakuchi and
co-workers reignited the interest in these self reactive T cells that
escape negative selection and express high levels of CD25 on theirsurface [97]. These naturally occurring self reactive T cells with
immunoregulatory properties are proposed to be a main player
in preventing the emergence of autoimmunity in the periphery. If
the gain-of-function hypothesis is correct, Treg function may be
compromised leading to deﬁcient regulation of autoreactive T cells
in the periphery.
Finally, more work is required in the context of other immune
cells. Immunoreceptor signalling is often governedbySrc andSykki-
nases which are both substrates of Lyp. Lyp potentially inﬂuences
any given immunoreceptor that utilises the Src and Syk kinases
and some of these receptors have been shown to be important con-
tributors to autoimmune disease. Recognition of immune deposits
through Fc receptors in lupus by immune cells is thought to be ama-
jor driving force of disease [98]. One study has already highlighted
the importance of Lyp in NK cell proliferation in vitro [99]. NK cells
have been demonstrated to contribute to autoimmunity in various
ways, and an imbalance of these cells in vivo might tip the scale in
favour of an autoimmune phenotype [100].
11. Concluding remarks
In this reviewwe have summarised the current understanding of
the biology of an allelic variant of the PTPN22 gene resulting in an
arginine to tryptophansubstitutionwithinan importantpolyproline
binding motif that mediates SH3 domain interactions. Much work
remains to be done in order to understand R620W and the non-dis-
ease associated R620. Its absence in African and Asian populations
begs the question of its importance in human immunity and why
it has been selected for in some populations and not others. Protec-
tion from infection and susceptibility to autoimmune disease has
been proposed to have a reciprocal relationship.
Despite a wealth of genetic studies implicating R620W as risk
factor for multiple autoimmune diseases, functional studies
exploring how the mutant phosphatase contributes to disease
development have lagged behind. While T and B cell receptor sig-
nalling have been the main focus of most investigations to date,
other immune cell types must also be investigated so as to gain a
more holistic understanding of PTPN22 function both in sickness
and in health.
New insights from the PEP deﬁcient mouse may help to deﬁne
the functions of Lyp in different cell lineages. Indeed, mouse stud-
ies have contributed to our understanding of Lyp function and fur-
ther studies may provide valuable information that can then be
used to direct future functional studies in humans. It is also imper-
ative to understand any functional discrepancies between PEP and
Lyp that may set these two phosphatases apart, as well as common
functions that bring them together.
A gain-of-function mutation may present a situation in which
small molecule inhibitors might be of value. In order for the ther-
apeutic potential of R620W to be realised, a clear consensus must
be reached as to the nature of the mutation ie gain- or loss-of-func-
tion. Understanding perturbations caused by R620W in signalling
cascades that predisposes individuals to pathogenic autoimmunity
remains a formidable challenge.
PTPN22 remains a fascinating gene candidate for further study
and its promiscuous association with multiple autoimmune dis-
eases might indicate that a common, hitherto unappreciated mech-
anism underlying the development of autoimmune disease. Such a
ﬁnding would have huge implications in our current understand-
ing of autoimmunity and may be of therapeutic beneﬁt.
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